Quick Answer
CRESCENT BIOPHARMA, INC. reported Net Income Loss of -$153.94 million for the year ending 2025.
- CRESCENT BIOPHARMA, INC. showed a decrease of -306.4% in Net Income Loss from 2024 to 2025.
- This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$6.62 million | Q4 2014: -$7.39 million | Q1 2015: -$7.11 million | Q2 2015: $10.39 million | Q3 2015: -$7.17 million | Q4 2015: -$8.88 million | Q1 2016: -$7.55 million | Q2 2016: -$8.07 million | Q3 2016: -$7.85 million | Q4 2016: -$8.33 million | Q1 2017: -$7.93 million | Q2 2017: -$8.14 million | Q3 2017: -$7.95 million | Q4 2017: -$9.26 million | Q1 2018: -$11.51 million | Q2 2018: -$11.28 million | Q3 2018: -$11.58 million | Q4 2018: -$13.91 million | Q1 2019: -$14.08 million | Q2 2019: -$15.83 million | Q3 2019: -$13.25 million | Q4 2019: -$14.73 million | Q1 2020: -$7.66 million | Q2 2020: -$14.08 million | Q3 2020: -$13.72 million | Q1 2021: -$14.27 million | Q2 2021: -$14.40 million | Q3 2021: -$17.33 million | Q1 2022: -$14.65 million | Q2 2022: -$13.27 million | Q3 2022: -$8.52 million | Q1 2023: -$10.36 million | Q2 2023: -$8.26 million | Q3 2023: -$9.20 million | Q1 2024: -$10.74 million | Q2 2024: -$10.10 million | Q3 2024: -$9.82 million | Q3 2024: -$2.63 million | Q4 2024: -$17.87 million | Q1 2025: -$15.15 million | Q2 2025: -$21.79 million | Q3 2025: -$24.61 million.
- Over the full 14 years of available data (2012 to 2025), CRESCENT BIOPHARMA, INC.'s Net Income Loss has declined by 4,310.6%.
- Historical annual values: Fiscal year 2025: -$153.94 million | Fiscal year 2024: -$37.88 million | Fiscal year 2023: -$36.90 million | Fiscal year 2022: -$46.69 million | Fiscal year 2021: -$63.43 million | Fiscal year 2020: -$51.03 million | Fiscal year 2019: -$57.89 million | Fiscal year 2018: -$48.27 million | Fiscal year 2017: -$33.28 million | Fiscal year 2016: -$31.81 million | Fiscal year 2015: -$12.77 million | Fiscal year 2014: -$11.12 million | Fiscal year 2013: -$10.61 million | Fiscal year 2012: $3.66 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: